Tiburio has assembled a world class team of experts in advancing drugs for patients in need.
Abraham N. Ceesay
Chief Executive Officer
Abraham has over 17 years of experience in leading biopharmaceutical companies and commercializing innovative therapeutic products. Prior to joining Tiburio, he served as chief operating officer at scPharmaceuticals where he developed and led all operational and commercial aspects of the company. He was integral in raising more than $140 million in private and public capital as well as closing the company’s initial public offering. Prior to joining scPharmaceuticals, he served as vice president, sales, marketing, and commercial operations at Keryx Biopharmaceuticals and spent four years at Ironwood Pharmaceuticals as vice president of marketing. He also held responsibility for the management of the U.S. P&L, leadership of the Linzess® brand team and co-promotion collaboration with Forest Laboratories/Allergan. Previously, Abraham was at Genzyme/Sanofi, initially as a field sales specialist and ultimately as the director, Renal Global Marketing, in which capacity he led the global launch of Renvela® and held global marketing responsibility for the company’s renal franchise (Renagel®, Renvela®, Hectorol®).
Abraham serves on the Board of Advisors for Life Science Cares and the Board of Directors for Food for Free. He holds a bachelor’s degree from Ithaca College, and a Master of Business Administration from Suffolk University’s Sawyer School of Management.
Shi Yin Foo, MD, PhD, MMSC
Acting Chief Medical Officer
Shi Yin brings 20 years of experience both as a practicing physician and as a catalyst in advancing innovative new programs through the various stages of drug development. She has expertise in a breadth of disease areas, including cardiorenal, immunology/inflammation and rare diseases, as well as an interest in novel and adaptive clinical trial designs.
Prior to joining Tiburio and Cydan, Shi Yin was the chief medical officer of Cardioxyl Pharmaceuticals and a translational medicine expert at the Novartis Institutes for Biomedical Research, where she was responsible for the establishment and development of multiple novel programs in heart failure and the cardiorenal space, including rare disease indications. Shi Yin is the founder of Orchard Biomedical Consulting, which serves a variety of biotech and pharma partners in broad disease indications.
She is also acting chief medical officer for Cydan NewCo, Imara Inc., which launched in 2016.
Shi Yin received her MD and PhD in immunology from Stanford University, and a MMSc in clinical science from the Clinical Investigator Training Program at Harvard Medical School. She was clinical faculty at the Massachusetts General Hospital and Harvard Medical School, and a dual Diplomate of the American Board of Internal Medicine and in Cardiology.
Heather Halem, PhD
Vice President, Research
Heather brings more than 17 years of pharmaceutical experience to Tiburio with strong expertise in rare endocrine and metabolic diseases, oncology and in developing pharmacology models of disease. A senior, cross-functional project team leader, Heather has direct experience leading research programs that have taken molecules from early identification to clinic candidates.
Prior to joining Tiburio, Heather spent 15 years at Ipsen Bioscience, serving most recently as director, endocrine modeling. In the role, she led research project teams from early-stage target identification and concept assessment through lead optimization and into the clinic. She also initiated and directed in vivo biology research efforts and strategies for all endocrine projects. Previously, Heather was a senior scientist at Genome Therapeutics identifying novel gene targets for neurodegenerative diseases and served as a research assistant at Boston University, Massachusetts General Hospital and New England Medical Center.
Heather earned her BA in biology from Macalester College in St. Paul, Minn., and her PhD in biology from Boston University. She holds two patents and has authored numerous papers in leading peer-reviewed journals.